Business

Title Due Date Maximum Award Amount Description
New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed) $1,838,436.00

This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to better capture this variability in responses to chemical exposure in the population based on individual genetic susceptibility.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341632
RPIC COOPERATIVE AGREEMENT $250,000.00

The Rural Placemaking Innovation Challenge (RPIC) provides planning support, technical assistance, and training to communities to foster placemaking activities in rural communities. Funds can help enhance capacity for broadband access, preserve cultural and historic structures, and support the development of transportation, housing, and recreational spaces. Applicants must demonstrate existing and proposed partnerships with public, private, philanthropic, Tribal and community partners to provide assistance in implementing the placemaking plan. This funding announcement supports the delivery of technical assistance and training in visioning, planning, and assisting communities to implement placemaking efforts in rural communities under the Rural Placemaking Innovation Challenge.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341609
Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only) $2,500,000.00

To ensure that digital therapeutics that have been or are in the development for SUD are adopted, this funding opportunity concept aims to fund clinical trials that will generate convincing data to improve adoption by the payors.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341593
NIDA Program Project Grant Applications (P01 Clinical Trial Optional) Varies

This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341558
Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed) $2,500,000.00

This Funding Opportunity Announcement (FOA) seeks grant applications from small business concerns (SBCs) to develop psychoplastogenic compounds and related models for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341426
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) $600,000.00

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341389
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) $600,000.00

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341374
Lead and Healthy Homes Technical Studies (LHHTS) Grant Program Pre- and Full Application $1,000,000.00

HUD is funding studies to improve HUD's and the public's knowledge of housing-related health and safety hazards and to improve or develop new hazard assessment and control methods, with a focus on lead and other key residential health and safety hazards. HUD is especially interested in applications that will advance our knowledge on priority healthy homes issues by addressing important gaps in the science related to the accurate and efficient identification of hazards and the implementation of cost-effective hazard mitigation. This includes studies using implementation sciences in identifying specific conditions under which proven residential environmental hazard interventions in targeted housing types and residential settings can be sustained to improve intervention efficiency and efficacy.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341221
Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional) $1,500,000.00

oAs of May 18, 2021, 36 US states and four territories allow for the medical use of cannabis products. Current evidence from global database registries and other patient reported outcomes incorporate information from thousands of patients, but much of the evidence is based on anecdotal reports rather than possessing the robustness of randomized clinical trials, and these different types of sources are not always in agreement. As many patients are already using cannabis products for medicinal applications, it is important to identify the evidence that exists and as it evolves, and to harmonize and coordinate this information to maximize the potential benefits to patients while minimizing harmful effects. The goal of this cannabis registry is to gather information regarding medicinal cannabis products used as well as timing of, reasons for, and outcomes of use and impacts on other non-cannabis medication (e.g., opioids) use. This coordinating center will also lead efforts in archiving and analyzing these data, as well as disseminating their findings.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341134
Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed) Varies

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341135